Chief Operating Officer
Paul Rennie, BSc, MBM, MS

Mr. Rennie has over 25 years experience in marketing and business development within the Australian biomedical and pharmaceutical industry. He was formerly Director of Business Development for Soltec, a wholly owned subsidiary of F H Faulding & Co., Ltd, with focus on developing improved pharmaceutical drug delivery systems. Previously, as Business Development Manager for the Biosciences Division of Bonlac, he led the commercialisation strategies and licensing negotiations between Bonlac and multinational global oral care and health care/nutritional companies, including Johnson & Johnson, Procter & Gamble, and SmithKlineBeecham, and successfully concluded licensing of Bonlac's CPP-ACP technology to Warner Lambert. Between 1990-1994 he held various positions with the global pharmaceutical company Merck Ltd, where as National Sales and Marketing Manager he was responsible for Australia-wide sales of pharmaceuticals, analytical reagents, environmental monitoring products, and scientific research products. In this capacity, Mr. Rennie implemented a new strategic plan which contributed to transforming Merck Australia from having a loss in 1993 to record sales and profits in 1996.

Vice President, Operations
Suzanne Lipe BSc (Hons), PhD, LLB

Dr Lipe has strong development and commercial experience gained over almost 20 years in the pharmaceutical and biotech industry. She has negotiated with centres, set up and managed preclinical and clinical trial programs, including IND multi-centre studies, and had regulatory affairs responsibility for several multinational companies. Through a strong commercial focus, she developed the strategy and managed the launch of new products on to the market, particularly through her senior roles with the former ICI (now AstraZeneca), Rhone-Poulenc Rorer (now Aventis) and CSL. Dr Lipe has been a Managing Director, CEO and Board member of three biotechnology start-up companies and for four years prior to joining Mesoblast, she was Chief Operating Officer at Norwood Immunology. She is a member of the Pharmaceuticals Partnerships Program Committee of the Innovation Board (AusIndustry).

Vice President of Research and Clinical Affairs
James T. Ryaby, Ph.D., Cell Biology; B.A., Chemistry

A highly experienced clinical trials designer and director, Dr Ryaby joined Mesoblast as Vice President of Research and Clinical Affairs in March 2008. Previously, he held a similar role at United States publicly listed company, Orthologic Corporation. Dr Ryaby, who is based in the United States, has extensive expertise in clinical development of orthopaedic and bone regenerative technologies. Significantly, his accomplishments include successful execution of large, multi-centre Phase 3 clinical trials for publicly-listed US corporations. Since 1992, he has been an Adjunct Professor in the Department of Bioengineering at Arizona State University. He has co-authored 57 publications focusing on orthopaedics and cells. He is a professional member of the American Academy of Orthopaedic Surgeons, American Society for Bone and Mineral Research, International Cartilage Repair Society, International Society for Fracture Repair, North American Spine Society and the Orthopaedic Research Society.

Chief Financial Officer
Jenni Pilcher CA, BBS

Since qualifying as a Chartered Accountant with Price Waterhouse, Ms Pilcher has worked in corporate and business financial roles for high profile international companies in pharmaceuticals, FMCG (fast moving consumer goods) and services. Before joining Mesoblast as Financial Controller in 2007, she spent six years with ASX 200 Company, Spotless Group, progressing through a variety of financial roles. Previously Ms Pilcher worked in the finance teams at Cadbury Schweppes plc and international pharmaceutical group Medeva plc, both based in the United Kingdom . She was appointed Chief Financial Officer of Mesoblast in November 2007.

Clinical and Regulatory Affairs
Dr Donna L. Skerrett, MD, MS

Dr Skerrett has been involved in stem cell procurement, manipulation and transplantation for more than 10 years. She has most recently been Director of the Stem Cell Facilities at Weill-Cornell Medical Center in New York, and previously served as Associate Director of Transfusion Medicine at Columbia University's New York-Presbyterian Hospital. Dr Skerrett oversees clinical development of the antibody-based stem cell selection technology and in vitro culture processes, as well as the human clinical trial programs, while liaising closely with the FDA. She is an advisor to the New York State Department of Health on the progenitor cell committee and the governor's Council on Blood and Transfusion Services. Dr Skerrett has also been an adviser and committee member with the National Marrow Donor Program and the American Society of Hematology.

Vice President for Cartilage Regenerative Programs
Professor Peter Ghosh, BSc (Hons), PhD, DSc, FRACI, FRSC, CSc.

Associate Professor Peter Ghosh is recognised as an international authority on osteoarthritis and intervertebral disc disease and has authored more than 400 books, papers and book chapters in these fields. In 1999, Professor Ghosh was elected President and Director of the Institute of Bone and Joint Research of the University of Sydney at the Royal North Shore Hospital in Sydney, Australia. For ten years he was a Board member of the US-based Osteoarthritis Research Society International and remains a member of the journal's Editorial Board and is on the editorial boards of the APLAR Journal of Rheumatology and Current Rheumatology Reviews. He is past president of the Australian and New Zealand Orthopaedic Research Society and the Matrix Biology Society of Australia and New Zealand and was elected a Life Member of the International Hyaluronan Research Society. Professor Ghosh is presently a board member and director of four Australian biotechnology companies and a consultant for several international pharmaceutical companies.

Corporate Communications Director
Julie Meldrum

Winner of the League of American Communication Professionals Gold Magellan Award, Ms Meldrum has 30 years experience as a corporate communications and investor relations strategist, European foreign correspondent, political and business reporter and television and radio producer. She also served as a senior diplomat for 14 years promoting Australian policies and industries in the key markets of Japan , Hong Kong and Indonesia and has advised Prime Ministers, Cabinet Ministers and business leaders. Ms Meldrum previously worked in a similar role for Australian heart company, Ventracor Limited, where she devised and led the pivotal corporate communications and investor relations functions aimed at gaining access to international markets. She was appointed Corporate Communications Director of Mesoblast in September 2004.

About us
Organisation
Executive management
Scientific Advisory Board
Corporate Governance